Eyeworld

EW NEWS & OPINION 18 February 2017 Dr. Chan pointed to the devel- opment of the artificial cornea as another high point. "It still has a lot of challenges with patient complica- tions and management of long-term issues, but the fact that it's available for patients who otherwise would be bilaterally blind is amazing," Dr. Chan said. Appreciation of the ocular sur- face and understanding the manage- ment of dry eye and blepharitis have taken center stage over the past 20 years in EyeWorld. "I think the role of meibomian gland dysfunction has been further understood as contributing to patients' dry eye symptoms," Dr. Chan said. In man- aging this, omega-3 fatty acid has proven to have an impact, as have therapies like LipiFlow (TearScience, Morrisville, North Carolina) and MiBoFlo Thermoflo (MiBo Medical Group, Dallas). Dr. Donnenfeld credits past medical editors such as Marguerite McDonald, MD, Steve Lane, MD, Steve Obstbaum, MD, Dr. Holland, and David Chang, MD, as import- ant influencers, but stressed they have not been alone. "We've had some great editors for the last 20 years. We've had thousands of con- tributors, but we've only had one publisher, and that's Don Long," Dr. Donnenfeld said. "A lot of the qual- ity that you see today in EyeWorld can be directly attributed to Don's tireless work from behind the scenes to make certain that EyeWorld be- came the voice of anterior segment ophthalmology. I think we owe him a debt of gratitude." EW Editors' note: Dr. Chan has financial interests with Alcon, Allergan, Bausch + Lomb (Bridgewater, New Jersey), and TearLab (San Diego). Dr. Donnenfeld has financial interests with Abbott Medical Optics, Alcon, Allergan, Bausch + Lomb, Shire, Physician Recommended Nutriceuticals (Plymouth Meeting, Pennsylvania), and TLC Laser Centers. Dr. Holland has financial interests with Allergan, Shire, TearLab, and TearScience. Dr. Knorz has no financial interests related to his comments. Contact information Chan: clara.chan@gmail.com Donnenfeld: ericdonnenfeld@gmail.com Holland: eholland@holprovision.com Knorz: knorz@eyes.de the U.S., more studies will be com- ing out about different techniques, such as epithelial-on/epithelial-off indications." One of the overarching themes has been the evolution of corneal transplant surgery and the huge shift to lamellar corneal surgery, especially endothelial keratoplasty and DMEK, she said. It became possible to potentially pre- vent progression in young patients and avoid the need for keratoplasty. Clara Chan, MD, assistant professor, University of Toronto, and EyeWorld's current Cornea section editor, also pointed to crosslinking's approval as one of the highlights over the past 20 years. "We've had a few feature articles on that," she said. "Now that it's FDA approved in Another exciting development since 1996 is collagen crosslinking for corneal ectasia. With the advent of topography, keratoconus could be diagnosed much sooner, but little was being done for the condition. "Then DALK was introduced and got us much better outcomes for kerato- conus," Dr. Holland said. "But it was the advent of collagen crosslinking that totally changed the approach." NOW IN SINGLE-USE ! by DIAMATRIX IRIS SPECULUM 6.7mm near-circular dilation 30 day trial available, call 800.867.8081 No Pinching, Easily Rotates Visit our website Diamatrix.com for additional information New continued from page 17

• Cover